Animal models of Parkinson's disease and their applications

被引:6
作者
Park, Hyun Jin [1 ]
Zhao, Ting Ting [1 ]
Lee, Myung Koo [1 ]
机构
[1] Chungbuk Natl Univ, Dept Pharm, Res Ctr Bioresource & Hlth, Coll Pharm, 1 Chungdae Ro, Cheongju 28644, South Korea
来源
JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME | 2016年 / 6卷
基金
新加坡国家研究基金会;
关键词
Parkinson's disease; neurotoxin animal models; genetic animal models; adjuvant therapeutics;
D O I
10.2147/JPRLS.S85419
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disorder that occurs mainly due to the degeneration of dopaminergic neuronal cells in the substantia nigra. L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective known therapy for PD. However, chronic L-DOPA administration results in a loss of drug efficacy and irreversible adverse effects, including L-DOPA-induced dyskinesia, affective disorders, and cognitive function disorders. To study the motor and non-motor symptomatic dysfunctions in PD, neurotoxin and genetic animal models of PD have been widely applied. However, these animal models do not exhibit all of the pathophysiological symptoms of PD. Regardless, neurotoxin rat and mouse models of PD have been commonly used in the development of bioactive components from natural herbal medicines. Here, the main animal models of PD and their applications have been introduced in order to aid the development of therapeutic and adjuvant agents.
引用
收藏
页数:10
相关论文
共 121 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] Agid Y, 1987, MOVEMENT DISORD, V1, P166
  • [3] LRRK2 mutations and Parkinsonism
    Albrecht, M
    [J]. LANCET, 2005, 365 (9466) : 1230 - 1230
  • [4] DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase
    Andres-Mateos, Eva
    Perier, Celine
    Zhang, Li
    Blanchard-Fillion, Beatrice
    Greco, Todd M.
    Thomas, Bobby
    Ko, Han Seok
    Sasaki, Masayuki
    Ischiropoulos, Harry
    Przedborski, Serge
    Dawson, Ted M.
    Dawson, Valina L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (37) : 14807 - 14812
  • [5] THE DETERMINATION OF HYDROXYDOPAMINES AND OTHER TRACE AMINES IN THE URINE OF PARKINSONIAN-PATIENTS AND NORMAL CONTROLS
    ANDREW, R
    WATSON, DG
    BEST, SA
    MIDGLEY, JM
    WENLONG, H
    PETTY, RKH
    [J]. NEUROCHEMICAL RESEARCH, 1993, 18 (11) : 1175 - 1177
  • [6] BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13
  • [7] Paraquat and Parkinson's disease
    Berry, C.
    La Vecchia, C.
    Nicotera, P.
    [J]. CELL DEATH AND DIFFERENTIATION, 2010, 17 (07) : 1115 - 1125
  • [8] Localization of LRRK2 to membranous and vesicular structures in mammalian brain
    Biskup, Saskia
    Moore, Darren J.
    Celsi, Fulvio
    Higashi, Shinji
    West, Andrew B.
    Andrabi, Shaida A.
    Kurkinen, Kaisa
    Yu, Seong-Woon
    Savitt, Joseph M.
    Waldvogel, Henry J.
    Faull, Richard L. M.
    Emson, Piers C.
    Torp, Reldun
    Ottersen, Ole P.
    Dawson, Ted M.
    Dawson, Valina L.
    [J]. ANNALS OF NEUROLOGY, 2006, 60 (05) : 557 - 569
  • [9] Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice
    Blanchet, Julie
    Longpre, Fanny
    Bureau, Genevieve
    Morissette, Marc
    DiPaolo, Therese
    Bronchti, Gilles
    Martinoli, Maria-Grazia
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (05) : 1243 - 1250
  • [10] Blandini Fabio, 2008, Parkinsonism Relat Disord, V14 Suppl 2, pS124, DOI 10.1016/j.parkreldis.2008.04.015